A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

About the study

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma
Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1
Eastern cooperative oncology group performance status of 0 or 1

EXCLUSION CRITERIA

Exclusion Criteria:

High-grade lymphomas (Burkitt's or lymphoblastic)
Has cancer with symptomatic central nervous system (CNS) involvement
History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months

Other protocol-defined inclusion/exclusion criteria apply

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details

Contition

Neoplasms

Age (in years)

18+

Phase

Phase 1

Participants needed

230

Est. Completion Date

Aug 25, 2025

Treatment type

Interventional

Sponsor

Celgene

ClinicalTrials.gov identifier

NCT03783403

Study number

CC-95251-ST-001

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?